Valeant set to expand in Australia/Asia Pacific markets with iNova acquisition
This article was originally published in Scrip
Executive Summary
Continuing its buying spree, Valeant Pharmaceuticals is now set to strengthen its presence in the Australian and Asia Pacific markets having agreed to acquire iNova, a private pharmaceutical group which sells and distributes prescription and over-the-counter (OTC) products in Australia, New Zealand, Southeast Asia and South Africa. Valeant is buying the firm from Australian private equity firms, Archer Capital and Ironbridge and other minority management shareholders.